Floatz logo

ONO 7475

Advanced or Metastatic Solid Tumors

Ono Pharmaceutical Co., Ltd.Small moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

62 Active assets in the Advanced or Metastatic Solid Tumors cohort.

Asset / SponsorPhaseRating
Epirubicin
Hanmi Pharmaceutical Company Limited
Phase 1/2B
Pembrolizumab
Hanmi Pharmaceutical Company Limited
Phase 1/2B
Cyclophosphamide
Beijing Biotech
Phase 1/2B
Eloxatin
ASLAN Pharmaceuticals
Phase 1/2CCC
Pemigatinib
Incyte Corporation
Phase 2CCC

View all 50 →

Same molecule, other indications

ONO 7475 is also rated in:

Recurrent Non-Small Cell Lung CancerDormant
CC
Indicative ·
47 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
EGFR Mutation-Related TumorsDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →